July 2, 2021 Journal article Open Access

Alshafie, Walaa; Fotouhi, Maryam; Southern, Kathleen; McPherson, Peter S.; Laflamme, Carl

DataCite XML Export

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="DOI">10.5281/zenodo.5061824</identifier>
  <creators>
    <creator>
      <creatorName>Alshafie, Walaa</creatorName>
      <givenName>Walaa</givenName>
      <familyName>Alshafie</familyName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0001-7999-1297</nameIdentifier>
      <affiliation>Montreal Neurological Institute</affiliation>
    </creator>
    <creator>
      <creatorName>Fotouhi, Maryam</creatorName>
      <givenName>Maryam</givenName>
      <familyName>Fotouhi</familyName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0001-8937-4719</nameIdentifier>
      <affiliation>Montreal Neurological Institute</affiliation>
    </creator>
    <creator>
      <creatorName>Southern, Kathleen</creatorName>
      <givenName>Kathleen</givenName>
      <familyName>Southern</familyName>
      <affiliation>Montreal Neurological Institute</affiliation>
    </creator>
    <creator>
      <creatorName>McPherson, Peter S.</creatorName>
      <givenName>Peter S.</givenName>
      <familyName>McPherson</familyName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0001-7806-5662</nameIdentifier>
      <affiliation>Montreal Neurological Institute</affiliation>
    </creator>
    <creator>
      <creatorName>Laflamme, Carl</creatorName>
      <givenName>Carl</givenName>
      <familyName>Laflamme</familyName>
      <nameIdentifier nameIdentifierScheme="ORCID" schemeURI="http://orcid.org/">0000-0001-5906-025X</nameIdentifier>
      <affiliation>Montreal Neurological Institute</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Antibody Characterization Report for Ataxin-2</title>
  </titles>
  <publisher>Zenodo</publisher>
  <publicationYear>2021</publicationYear>
  <subjects>
    <subject>Ataxin-2</subject>
    <subject>Spinocerebellar ataxia type 2 protein</subject>
    <subject>Trinucleotide repeat-containing gene 13 protein</subject>
    <subject>ATXN2</subject>
    <subject>atxn2</subject>
    <subject>Q99700</subject>
    <subject>antibody characterization</subject>
    <subject>antibody validation</subject>
    <subject>Amyotrophic lateral sclerosis</subject>
    <subject>ALS-RAP</subject>
  </subjects>
  <dates>
    <date dateType="Issued">2021-07-02</date>
  </dates>
  <language>en</language>
  <resourceType resourceTypeGeneral="JournalArticle"/>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://zenodo.org/record/5061824</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsVersionOf">10.5281/zenodo.5061823</relatedIdentifier>
    <relatedIdentifier relatedIdentifierType="URL" relationType="IsPartOf">https://zenodo.org/communities/openlabnotebooks</relatedIdentifier>
    <relatedIdentifier relatedIdentifierType="URL" relationType="IsPartOf">https://zenodo.org/communities/sgc-opennotebook</relatedIdentifier>
    <relatedIdentifier relatedIdentifierType="URL" relationType="IsPartOf">https://zenodo.org/communities/ycharos</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="https://creativecommons.org/licenses/by/4.0/legalcode">Creative Commons Attribution 4.0 International</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">&lt;p&gt;Head to head comparison of available commercial antibodies against Ataxin-2 by immunoblot (Western blot), immunoprecipitation and immunofluorescence.&lt;/p&gt;

&lt;p&gt;This work is part of the ALS-Reproducible Antibody Platform (ALS-RAP). ALS-RAP&amp;nbsp;was created as a public-private partnership by three leading ALS charities - the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.&lt;/p&gt;</description>
  </descriptions>
</resource>